Click the NIMH number to see more information about the compound.
Click the order button to order that compound.
Type within the boxes at the top of any column to search for items in
the catalog.
| MH No. | Compound Name | Indication | Order |
|---|---|---|---|
| M-904 | Pramipexole | Dopamine receptor agonist; used to treat Parkinson's disease, restless legs syndrome | |
| E-902 | Escitalopram oxalate | Serotonin 5-HT reuptake inhibitor, antidepressant, antixiolytic | |
| O-902 | Oxcarbazepine | An anticonvulsant used to treat seizures in patients with epilepsy | |
| M-905 | Mirtazapine | Serotonin & noradrenergic antagonist, an antidepressant used to treat severe depression | |
| L-902 | Lamotrigine | Voltage-sensitive sodium channel inhibitor, an anticonvulsant used to treat seizures and bipolar disorder. | |
| V-901 | Venlafaxine | Serotonin and norepinephrine reuptake inhibitor used to treat major depressive disorders, generalized anxiety disorder , panic disorder, social phobia, and chronic pain | |
| A-907 | Aripiprazole | An atypical antipsychotic used to treat schizophrenia and bipolar mania, acting on dopamine and serotonin receptors | |
| D-908 | Duloxetine hydrochloride | Serotonin & norepinephrine reuptake inhibitor, used to treat major depressive disorder, generalized anxiety disorder, fibromyalgia, neuropathic pain | |
| B-903 | Bupropion hydrochloride | Dopamine & norepinephrine reuptake inhibitor, nicotine receptor antagonist, used as an antidepressant and smoking cessation therapy | |
| R-903 | Ropinirole hydrochloride | Dopamine D2, D3, D4 receptor agonist used to treat treat Parkinson's disease and restless legs syndrome | |
| S-909 | Sertraline hydrochloride | Serotonin reuptake inhibitor; used to treat used to treat major depressive disorder, obsessive–compulsive disorder, panic disorder, post-traumatic stress disorder, premenstrual dysphoric disorder, and social anxiety disorder | |
| P-902 | Paroxetine hydrochloride | A serotonin reuptake inhibitor with antidepressant and anxiolytic properties. | |
| Z-903 | Ziprasidone hydrochloride | Dopamine D2 , Serotonin 5-HT2A, 5HT1D receptor antagonist, 5-HT1 receptor agonist; an atypical antipsychotic used to treat schizophrenia and bipolar disorder. | |
| G-901 | Gabapentin | Gamma aminobutyric acid (GABA) analog, anticonvulsant used to treat partial seizure, neuropathic pain, hot flashes, and restless legs syndrome. | |
| D-909 | Donepezil | Reversible acetylcholinesterase inhibitor, used to treat Alzheimer's disease | |
| C-916 | Coenzyme A-S-acetyl-7-hydroxynaphthylethylamine | Ligand for melatonin rhythm enzyme arylalkylamine-N-acetyltransferase (AANAT). | |
| C-915 | Carnosine-d7 | Use as LC/MS internal standard to quantify carnosine | |
| A-908 | Anserine-d4 | Stable isotope labeled anserine | |
| F-905 | 3-Fluoro-5-{2-[2-(fluoromethyl)thiazol-4-yl]ethynyl}benzonitrile | Metabotropic glutamate mGluR5 PET ligand reference standard | |
| B-904 | 3-{2-[2-(Bromomethyl)thiazol-4-yl]ethynyl}-5-fluorobenzonitrile | Metabotropic glutamate mGluR5 PET imaging ligand precursor | |
| D-910 | N-Desmethylolanzapine | Olanzapine metabolite | |
| P-903 | 3-{2-[4-(6-Fluorobenzo[d]isoxazol-3-yl)-1-piperidyl]ethyl}-7-hydoxy-4-methyl-1,5-diazabicyclo[4.4.0]deca-3,5-dien-2-one | Resperidone metabolite; atypical antipsychotic used to treat schizophrenia and schizoaffective disorder | |
| T-910 | Tianeptine, sodium salt | Atypical agonist of the mu-opioid receptor used in the treatment of major depressive disorder, anxiety, asthma, and irritable bowel syndrome. | |
| B-905 | N-Bromoacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline | Peripheral benzodiazepine receptor PET ligand labeling precursor | |
| F-906 | N-Fluoroacetyl-N-(2,5-dimethoxybenzyl)-2-phenoxyaniline | Peripheral benzodiazepine receptor PET ligand reference standard | |
| R-905 | N-(2-Aminoethyl)-5-(3-fluorophenyl)-4-thiazole carboxamide hydrochloride | Serotonin 5-HT2, 5-HT3, and histamine 1 H1 receptor antagonist used an atypical antidepressant | |
| H-909 | N-(2-Hydroxybenzyl)-N-(4-phenoxypyridin-3-yl)acetamide | Peripheral benzodiazepine receptor PET imaging ligand precursor | |
| M-907 | N-(2-Methoxybenzyl)-N-(4-phenoxypyridin-3-yl)acetamide | Peripheral benzodiazepine receptors PET imaging ligand reference standard | |
| M-911 | 3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone O-Methyl-oxime | Metabotropic glutamate mGluR5 antagonist | |
| M-912 | 3-(6-Methyl-pyridin-2-ylethynyl)-cyclohex-2-enone oxime | mGlu5 receptors PET imaging ligand precursor | |
| M-908 | (±)-2-[Di(phenyl)methanesulfinyl]acetamide | Dopamine reuptake inhibitor with wakefulness-promoting activity | |
| M-909 | R-(–)-[2-(Diphenyl)methanesulfinyl]acetamide | Dopamine reuptake inhibitor; (R)-(-) enantiomer of Modafinil with a longer duration of action and increased wakefulness promoting activity | |
| M-910 | S-(+)-[2-(Diphenyl)methanesulfinyl]acetamide | (S)-(+) enantiomer of Modafinil | |
| M-913 | 2-[4’-(Methylamino)phenyl]-6-hydroxybenzothiazole | Aggregated amyloid protein ligand; thioflavin-T analog; PET imaging agent Pittsburgh Compound-B (PIB) reference standard. | |
| A-909 | 2-(4’-Aminophenyl)-6-methoxymethoxybenzothiazole | beta-amyloid plaque PET imaging agent [Pittsburgh Compound-B (PIB)] precursor | |
| A-911 | 6-Aminomethyl-3-methyl-4H-1,2,4-benzothiadazine-1,1-dioxide hydrochloride | Taurine antagonist | |
| A-910 | (2S,3S,4R,5R,E)-N-Ethyl-3,4-dihydroxy-5-(6-(4-(6-(2-(4-(2-(4,4-difluoro-4,4a-dihydro-5-(thiophen-2-yl)4-bora-3a,4a-diaza-s-indacene-3-yl)vinyl)phenoxy)acetamido)hexanamido)butylamino)-9H-purin-9-yl)-tetrahydrofuran-2-carboxamide (ABEA-X-BY630) | Red-emitting fluorescent adenosine A3 receptor agonist | |
| D-912 | 2-{4-[4-(2-Hydroxyphenyl)piperazin-1-yl]butyl}-4-methyl-1,2,4-triazine-3,5-(2H,4H)-dione | 5-HT1A receptor PET imaging ligand precursor | |
| C-917 | 2-{4-[4-(2-Methoxyphenyl)piperazin-1-yl]butyl}-4-methyl-1,2,4-triazine-3,5-(2H,4H)-dione | 5-HT1A receptor PET imaging ligand reference standard | |
| B-906 | 8-Bromo-6-phenyl-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylic acid ethyl ester | Benzodiazepine intermediate for preparation of novel anxiolytic agent | |
| M-914 | 1-(2-Methylbenzoxazol-6-yl)-3-[1,5]-naphthyridin-4-yl-urea | Orexin subtype 1 antagonist | |
| I-905 | 2-Isopropylpentanoic acid | Non-teratogenic constitutional isomer of the anticonvulsant drug valproic acid | |
| S-910 | (R)-5,6-Dihydro-5-(methylamino)-4H-imidazo[4,5,1-ij]quinolin-2(1H)-one maleate | Dopamine D2 receptor agonist | |
| D-914 | (+)-(2R,3R,11bR)-10-Methoxy-3-(2-methylpropyl)-9-[11-(2,4,6-triethynylphenoxy)undecyloxy]- 1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-ol | Dihydrotetrabenazine derivative for preparation of magnetic resonance imaging (MRI) agent. | |
| C-918 | 3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamide | Metabotropic glutamate mGluR5 positive allosteric modulator | |
| B-907 | N-benzo[1,3]dioxol-5-yl-2-[5-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H purin-8-yl)-1-methyl- 1H-pyrazol-3-yloxy]acetamide | A2B adenosine receptor antagonist | |
| M-915 | 5-[(6-{[(5a,6a)-7,8-Didehydro-4,5-epoxy-3-hydroxy-17-methylmorphinan-6-yl]oxy}hexyl)- disulfanyl]-2-nitrobenzoic acid | Morphine derivative for preparation of protein disulfide conjugate | |
| N-903 | 2-Amino-1-(3,4-ditrimethylacetoxyphenyl)ethanol hydrochloride | Dipivalyl derivative and prodrug of norepinephrine | |
| F-907 | 2-Amino-1-(3,4-ditrimethylacetoxy-6-fluorophenyl)ethanol hydrochloride | Dipivalyl derivative and prodrug of 6-fluoronorepinephrine | |
| A-912 | (Sp)-Adenosine 3',5'-cyclic monophosphorothioate triethylammonium salt | Protein kinase A agonist | |
| B-909 | DL-threo-ß-Benzyloxyaspartic acid | Excitatory amino acid transporters inhibitor | |
| S-911 | SKF-83566 hydrobromide | Dopamine D1 receptor antagonist | |
| B-912 | {(R,S)-[(S)-1-(4-Bromophenyl)-ethylamino]-(2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-methyl}phosphonic acid hydrochloride | NMDA receptor antagonist | |
| D-917 | (R)-(+)-a-(2,3-Dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol | Serotonin 5-HT2A receptor antagonist | |
| A-917 | (3-Aminopropyl)(diethoxymethyl)phosphinic acid | GABAB receptor antagonist | |
| P-904 | Phenazepam | GABAA receptor allosteric modulator used to treat psychiatric schizophrenia and anxiety | |
| B-913 | Bromazepam | GABAA receptor allosteric modulator, a benzodiazepine derivative drug for the treatment of anxiety or panic attacks | |
| E-903 | Estazolam | GABAA receptor allosteric modulator, a benzodiazepine derivative drug for the treatment of insomnia | |
| A-918 | 4-Amino-1-tert-butyl-3-(1’-naphthylmethyl)pyrazolo[3,4-d]pyrimidine | Tyrosine kinase inhibitor | |
| S-912 | N-(1-Methyl-1H-indol-5-yl)-N'-(3-methylisothiazol-5-yl)urea | 5-HT2B receptor antagonist | |
| P-905 | Methyl (8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazol[1,5-a][1,4]benzodiazepin-3-yl)methyl ether | a5 GABAA receptor inverse agonist | |
| C-921 | 4-[5-(4-Methylphenyl)-3-trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide | Selective cyclooxygenase-2 (COX-2) inhibitor | |
| C-922 | 4-Chloro-2-(4,5-dihydro-1H-imidazol-2-yl)-2,3-dihydro-1H-isoindole Hydroiodide | I2 imidazoline receptor ligand | |
| D-920 | Delorazepam | Active metabolite of the benzodiazepine drugs diclazepam and cloxazolam, GABAA receptor allosteric modulator, anxiolytic, skeletal muscle relaxant, hypnotic and anticonvulsant | |
| P-906 | (+)-(4aR,10bR)-3,4,4a,5,6,10b-Hexahydro-4-propyl-2H-naphth[1,2-b]-1,4-oxazin-9-ol hydrochloride | Dopamine D2/3 receptor agonist; PET ligand reference standard. | |
| D-919 | (+)-(4aR,10bR)-3,4,4a,5,6,10b-Hexahydro-2H-naphtho[1,2-b]-1,4-oxazine-9-ol hydrochloride | Dopamine D2/3 receptors PET ligand labeling precursor | |
| N-905 | (-)-(2S,4R)-1-{(3R)-5-Chloro-1-[(2,4-dimethoxyphenyl)sulfonyl]-3-(2-methoxyphenyl)-2-oxo-2,3-dihydro-1H-indol-3-yl}-4-hydroxy-N,N-dimethyl-2-pyrrolidine-carboxamide | Orally-active non-peptide vasopressin V1b receptor antagonist | |
| C-924 | N-[2-[4-(3-Cyanopyridin-2-yl)piperazin-1-yl]ethyl]-3-methoxybenzamide | Dopamine D4 receptor PET ligand precursor | |
| C-925 | N-[2-[4-(3-Cyanopyridin-2-yl)piperazin-1-yl]ethyl]-3-hydroxybenzamide | Dopamine D4 receptor PET ligand labeling precursor | |
| B-914 | Benperidol | Dopamine D2 receptor antagonist, antipsychotic, neuroleptic, treatment for hypersexuality syndromes | |
| M-917 | N-Methylbenperidol | Antipsychotic; dopamine D2 receptors PET ligand reference standard | |
| M-918 | (RS)-1-[3-(Trimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydroisobenofuran-5-carbonitrile iodide | Peripherally restricted selective serotonin reuptake inhibitor | |
| D-921 | 1-[2-(3,4-Dimethoxyphenyl)ethyl]-4-(3-phenylpropyl)piperazine dihydrochloride | Sigma-1 receptor agonist | |
| D-922 | 4-[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]-N-methyl-2,2-diphenylbutanamide hydrochloride | Loperamide metabolite, P-glycoprotein PET reagent reference standard, P-glycoprotein inhibitor | |
| B-915 | (1-Butylpiperidin-4-yl)methyl 4-amino-3-methoxybenzoate | Serotonin 5-HT4 receptor agonist | |
| B-916 | (1-Butylpiperidin-4-yl)methyl 4-amino-3-hydroxybenzoate | Serotonin 5-HT4 receptor agonist | |
| V-903 | 2-Ethyl-3-methylvaleramide | Structural isomer of valpromide, a valproic acid prodrug; valnoctamide is not biotransformed into its homologous acid, valnoctic acid, in vivo; used as a sedative-hypnotic. | |
| M-919 | 4-[2-(Methylthio)phenyl]-N-(1,2,3,4-tetrahydronaphthalen-1-yl)-1-piperazinehexanamide hydrochloride | 5-HT7 receptor agonist | |
| N-906 | 4-Nitrophenyl-4-[bis(1,3-benzodioxol-5-yl)(hydroxy)methyl]piperidine-1-carboxylate | Monoacylglycerol lipase (MAGL) inhibitor | |
| H-910 | N-[2-(5-Hydroxy-6-fluoro-1H-indol-3-yl)ethyl]-2-oxopiperidine-3-carboxamide (6-Fluoro-HIOC) | Fluorinated HIOC derivative; selective TrkB receptor agonist; neuroprotectant | |
| T-911 | N-[2-(2-Trifluoromethyl-5-hydroxy-1H-indol-3-yl)ethyl]-2-oxopiperidine-3-carboxamide | Fluorinated HIOC derivative | |
| V-904 | 5-{4-[4-(5-Cyano-1H-indol-3-yl)butyl]piperazin-1-yl}-1-benzofuran-2-carboxamide dihydrochloride | Selective serotonin reuptake inhibitor and 5-HT1A receptor partial agonist, used to treat major depressive disorder. | |
| B-917 | Buprenorphine hydrochloride | High affinity partial mu-opioid receptor agonist, used to treat opioid use disorder, acute pain, and chronic pain | |
| C-927 | (+)-6-((R)-2-{2-[4-(4-Chlorophenoxy)piperidin-1-yl]ethyl}pyrrolidine-1-sulphonyl)-1H-indole hydrochloride | High-affinity, selective 5-HT7 antagonist | |
| C-928 | (-)-6-((S)-2-{2-[4-(4-Chlorophenoxy)piperidin-1-yl]ethyl}pyrrolidine-1-sulphonyl)-1H-indole Hydrochloride | Isomer of 5-HT7 antagonist SB-656104-A. | |
| C-929 | Clozapine-N-oxide | Clozapine metabolite, DREADD ligand | |
| L-904 | 2-(6-Fluoro-1H-indol-3-yl)-N-(3-(2,2,3,3-tetrafluoropropoxy)benzyl)ethanamine hydrochloride | Selective 5HT6 receptor antagonist | |
| L-905 | 9-Isopropyl-N-[3-(trifluoromethyl)benzyl]-9H-purin-6-amine | CK1, ERK2 and CDK7 kinases inhibitor that results in a lengthening of circadian periods | |
| L-906 | N-(1-(4-Iodobenzyl)piperidin-4-yl)-3-chlorophenylacetamide | Selective sigma-1 receptor ligand | |
| S-913 | 2-Bromo-N-[4-chloro-3-[[(3R)-1-methyl-3-pyrrolidinyl]oxy]phenyl]-4,5-dimethoxybenzenesulfonamide | Selective urotensin-II (UT) receptor antagonist | |
| A-919 | (±)-3-(4-Chlorophenyl)-3-[2-(dimethylamino)ethyl]-3,4-dihydro-1H-2-benzopyran-1-one hydrochloride | Non-peptide selective urotensin-II (UT) receptor agonist | |
| D-923 | 4-[4-(4-Chlorophenyl)-4-hydroxypiperidin-1-yl]-2,2-diphenylbutanamide | Loperamide metabolite, P-glycoprotein PET ligand labeling precursor | |
| P-907 | N-3-Pyridinyl-4-[[3-[[5-(trifluoromethyl)-2-pyridinyl]oxy]phenyl]methyl]-1-piperidinecarboxamide | Selective fatty acid amide hydrolase (FAAH) inhibitor. | |
| M-920 | (+)-4-(2-methoxyphenyl)-3,7,7-trimethyl-2H,4H,5H,6H,7H,8H,9H-pyrazolo[3,4-b]quinolin-5-one | Serine/threonine kinase glycogen synthase kinase-3 (GSK3) inhibitor | |
| M-921 | (-)-4-(2-methoxyphenyl)-3,7,7-trimethyl-2H,4H,5H,6H,7H,8H,9H-pyrazolo[3,4-b]quinolin-5-one | Serine/threonine kinase glycogen synthase kinase-3 (GSK3) inhibitor. | |
| D-924 | [5-(3,4-Dimethoxyphenyl)-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidin-3-yl][4-(2-methoxyphenyl)-1-piperazinyl]-methanone | An agent that enhances the amplitude of circadian activity and induces intracellular cAMP levels | |
| B-918 | 1,3-Bis(8-acetyleno-5,6-dihydro-5-methyl-6-oxo-4H-imidazo[1,5a][1,4]benzodiazepine-3-carboxy)propyl diester | Selective alpha5 GABA-A receptor antagonist/negative allosteric modulator | |
| N-907 | (±)-6-[(4-Chlorophenyl)(1H-1,2,4-triazol-1-yl)methyl]-1Hbenzo[d][1,2,3] triazole New! | Aromatase PET imaging ligand [11C]vorozole labeling precursor | |
| B-919 | (±)-trans-2-(4-Bromo-2,5-dimethoxybenzyl)-6-(2-methoxyphenyl)piperidine hydrochloride New! | Selective agonist for serotonin 5-HT2A receptor over the 5-HT2C receptor | |
| N-908 | (R)-6-[(4-Chlorophenyl)(1H-1,2,4-triazol-1-yl)methyl]-1H-benzo[d][1,2,3]triazole New! | Aromatase PET imaging ligand [11C]vorozole labeling precursor | |
| N-909 | (S)-6-[(4-Chlorophenyl)(1H-1,2,4-triazol-1-yl)methyl]-1H-benzo[d][1,2,3]triazole | Aromatase PET imaging ligand [11C]vorozole labeling precursor | |
| A-920 | 2-(5-{[3-(2-Aminoethyl)-1H-indol-5-yl]disulfanyl}-1H-indol-3-yl)ethan-1-amine dipicrate New! | A disulfide analog of serotonin | |
| L-907 | N-(4-(4-(4-Methoxyphenyl)-1,4-diazepan-1-yl)butyl)-4-(thiophen-3-yl)benzamide New! | D3 dopamine receptor ligand | |
| C-930 | (2S)-2-Amino-4-(2-amino-4-chlorophenyl)-4-oxobutanoic acid (4-Cl-KYN) trifluoroacetate New! | Prodrug of the glycine binding site NMDA receptor antagonist 7-chlorokynurenine | |
| P-908 | 11-(1-Piperazinyl)-5H-dibenzo[b,e][1,4]diazepine (C21) Dihydrochloride New! | DREADD ligand | |
| C-931 | N-{4-[4-(3-cyanophenyl)piperazin-1-yl]butyl}-4-(thiophen-3-yl)benzamide (MC-25-41) hydrochloride | Hight-affinity, selective D3 dopamine receptor ligand. | |
| D-925 | Deschloroclozapine (DCZ) Dihydrochloride | DREADD ligand | |
| J-902 | 8-Chloro-11-(4-ethylpiperazin-1-yl)-4-fluoro-5H-dibenzo[b,e][1,4]diazepine (JHU37160) Dihydrochloride New! | DREADD agonist with high affinity and potency for CNS applications. | |
| P-909 | 1-Methyl-7,8,9,10-tetrahydro-1H-6,10-methanoazapino[4,5-g]quinoxaline-2(6H)-one Hydrochloride (PSEM-792 HCl) New! | Ultrapotent chemogenetic agent | |
| P-910 | 2-Propoxy-7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline (PSEM-817) Hydrochloride New! | Ultrapotent chemogenetic agent | |
| T-912 | 8-methoxy-3-methyl-1H,2H,3H,4H,5H,6H-azepino[4,5-b]indole (Tabernanthalog) New! | A non-hallucinogenic agonist of the serotonin 5-HT2A receptor | |
| J-903 | 8-chloro-11-(4-ethylpiperazin-1-yl)-1-fluoro-5H-dibenzo[b,e][1,4]diazepine (JHU37152) dihydrochloride New! | DREADD agonist with high affinity and potency for CNS applications. | |
| J-904 | 8-Chloro-11-(4-ethylpiperazinyl)-5H-dibenzodiazepin-2-ol ([18F]JHU37107 Precursor) New! | A precursor to the high potency ligand for DREADD imaging. | |
| J-905 | 8-Chloro-11-(4-ethylpiperazin-1-yl)-2-fluoro-5H-dibenzo[b,e][1,4]diazepine dihydrochloride (JHU37107 dihydrochloride) | DREADD agonist with high affinity and potency for CNS applications. | |
| A-913 | (Rp)-Adenosine 3',5'-cyclic monophosphorothioate triethylammonium salt | Protein kinase A inhibitor | |
| A-915 | [5-Amino-1-(4-methoxyphenyl)sulfonylpyrazol-3-yl]benzoate | NS3 West Nile virus protease inhibitor | |
| A-904 | (R)-(-)-2-Amino-5-phosphonopentanoic acid | anticonvulsant; potent & selective NMDA receptor antagonist | |
| H-906 | 7alpha-(16-hydroxyhexadecyl)estra-1,3,5-trien-3,17beta-diol | Estrogen receptor modulator | |
| T-909 | 7alpha-[(3R/S,7R,11R)-3,7,11,15-tetramethylhexadecyl]estra-1,3,5-trien-3,17beta-diol | none | |
| H-905 | 7alpha-hexadecylestra-1,3,5-trien-3,17beta-diol | Estrogen receptor modulator | |
| C-711 | Coenzyme A-S-acetyltryptamine | Arylalkylamine N-acetyltransferase (AANAT) inhibitor | |
| C-504 | 7-Acetoxychlorpromazine hydrogen maleate | Putative chlorpromazine metabolite | |
| A-508 | Acetoxyethyldimethylethylammonium iodide | Acetylcholine analog | |
| B-807 | N-Acetyl-2-benzyltryptamine | Melatonin receptor antagonist | |
| D-523 | N-Acetyl-3,4-dihydroxy-beta-phenethylamine | Dopamine metabolite | |
| P-701 | N-Acetyl-3-hydroxy-4-methoxy-beta-phenethylamine | Dopamine derivative | |
| P-703 | N-Acetyl-4-methoxy-beta-phenethylamine | Phenethylamine derivative | |
| O-502 | N-Acetyl-DL-octopamine | Metabolite of biogenic amines | |
| A-906 | d7-N-Acetylserotonin | Stable isotope labeled melatonin MT1, MT2, and MT3 receptor agonist | |
| A-901 | N-Acetyltyramine | Biogenic amine, DOPA oxidase inhibitor | |
| A-903 | ADAM dDihydrochloride | Serotonin transporter ligand | |
| P-518 | N-(2-Adamantyl)piperazine dihydrochloride | Potential psychotropic | |
| A-502A | Adapiperazine dihydrochloride | Dopamine receptor antagonist, antiemetic, antipsychotic agent | |
| A-804 | N-(beta-Alanyl)-L-DOPA trifluoroacetate | DOPA analog | |
| A-805 | N-(beta-Alanyl)tyrosine trifluoroacetate | Bicyclic cage-like metal chelator | |
| A-512 | Alanylalanyl-6-hydroxydopamine hydrochloride | Analog of 6-Hydroxydopamine, a neurotoxin used to induce Parkinson's disease | |
| A-902 | N-beta-Alanyldopamine hydrochloride | DOPA analog, sclerotin precursor | |
| A-703 | Allantoxanamide | Uricase inhibitor | |
| A-510 | 2-Amino-1-(3,4,5-trimethoxyphenyl)ethanol | Mescaline/Amphetamine analog as possible hallucinogen or psychomimetic | |
| A-511 | 2-Amino-1-(3,4-dimethoxyphenyl)ethanol hydrochloride | Mescaline/Amphetamine analog as possible hallucinogen or psychomimetic | |
| A-514 | 6-Amino-2-chloro-9-(2'-O-methylsulfonyl-beta-D-xylofuranosyl)-9H-purine | Anticancer, thymidine monophosphate kinase inhibitor | |
| M-801 | (S)-2-Amino-2-methyl-4-phosphonobutanoic acid | Metabotropic glutamate mGluR2/3 agonist | |
| C-535 | 3-Amino-3,4-dihydro-7-hydroxycarbostyril | ||
| H-525 | 2-Amino-4-hydroxy-beta-phenethylamine dihydrobromide | beta-phenethylamine derivative | |
| I-707 | 2-(3-Amino-4-iodophenoxy)methylimidazoline dihydrochloride | Imidazoline-guaninidine binding site (IGRS) ligand, PET tracer precursor | |
| A-803 | (RS)-1-Amino-5-phosphonoindan-1-carboxylic acid | Rigid MPPG analog; selective group II metabotropic glutamate receptor antagonist | |
| T-510 | 2-Amino-DL-tyrosine | Tyrosine analog | |
| P-706 | 6-[2-(4-aminophenyl)ethyl-propylamino]-5,6,7,8-tetrahydronaphthalen-1-ol | Fluorescent ligand for dopamine receptors | |
| A-503 | 3-(2'-Aminobenzhydryloxy)tropane | Muscarinic M1 receptor ligand | |
| A-701 | cis-3-Aminocyclohexanecarboxylic acid | Selective neuronal GABA uptake inhibitor | |
| A-504 | 3-(beta-Aminoethyl)-5-hydroxybenzo[b]thiophene | Serotonin 5-HT1E ligand | |
| A-801 | (RS)-1-Aminoindan-1,5-dicarboxylic acid | Metabotropic glutamate mGluR1 antagonist | |
| N-701 | p-Aminophenethylspiperone | Dopamine D2 receptor antagonist; intermediate for photoaffinity agents | |
| I-706 | 2-(3-Aminophenoxy)methylimidazoline dihydrochloride | Imidazoline-guaninidine binding site (IGRS) ligand, PET tracer precursor | |
| S-704 | (±)-1-(4'-Aminophenyl)-7-bromo-8-methoxy-3-methyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine | Dopamine D1 receptor antagonist alkylating ligand precursor | |
| T-504 | 1-[2-(4-Aminophenyl)ethyl]-4-(3-trifluoromethylphenyl)piperazine dihydrochloride | Serotonin 5-HT1A receptor agonist | |
| M-502 | (±)-3-(2-Aminopropyl)-5-methoxyindole hydrochloride | Serotonin analog | |
| A-505 | 2-Aminotetralin hydrochloride | Serotonin 5-HT1A ligand | |
| A-507 | 5-Aminotryptamine dipicrate | Serotonin 5-HT1A receptor agonist | |
| A-905 | Aniracetam | D2/D3, nACh, & 5-HT2A receptor ligand, antidepressive agent; nootropic agent | |
| A-704 | APEC bis(trifluoroacetate) | Adenosine A2 receptor ligand | |
| A-705 | p-Aminophenylacetyl-APEC | Functionalized adenosine A2 ligand. | |
| A-914 | Asenapine maleate | Serotonergic, dopaminergic, and adrenergic receptor ligand, antipsychotic agent | |
| A-806 | Autonomium iodide | A natural product from sponge with a dual adrenergic and cholinergic properties | |
| Y-708 | (±)-4-Azido-5-deschloro-YM-09151-02 hydrochloride | Reference standard for YM-09151-2 analogs | |
| Y-704 | (±)-4-Azido-5-iodo-YM-09151-2 dihydrochloride | Dopamine D2 receptor photoaffinity ligand | |
| A-506 | 1-[2-(4-Azidophenyl)ethyl]-4-(3-trifluoromethylphenyl)piperazine hydrochloride | Serotonin 5-HT1A receptor photoaffinity labeling probe | |
| B-701 | N-[1-(2-Benzo[b]thiophenyl)cyclohexyl]piperidine hydrochloride | Dopamine uptake inhibitor with little affinity for PCP sites | |
| D-511 | 4'-Benzyloxy-2-dibenzylaminopropiophenone | Beta-phenylethylamine derivative | |
| P-517 | 4-Benzyloxy-3-methoxypyruvic acid | Pyruvic acid derivative | |
| C-505 | 8-Benzyloxy-7-methoxychlorpromazine | Chlorpromazine analog | |
| D-906 | FITC-APEC | Fluorescent adenosine A2a receptor ligand | |
| B-139 | (E)-7-Benzylidene-7-dehydronaltrexone hydrochloride | selective non-peptide delta1 opioid receptor antagonist | |
| S-703 | (±)-7-Bromo-1-[4'-(2-chloroethyl)aminophenyl]-8-hydroxy-3-methyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine dihydrobromide | Dopamine D1 receptor alkylating ligand | |
| C-705 | (±)-7-Bromo-1-[4’-bis(2-chloroethyl)aminophenyl]-8-hydroxy-3-methyl-2,3,4,5-tetrahydro-(1H)-3-benzazepine hydrochloride | Dopamine D1 receptor alkylating ligand | |
| B-806 | 1-Bromo-2,5-bis(4-hydroxystyryl)benzene | Amyloid imaging probe | |
| B-910 | 1-[4-(6-Bromo-benzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinolin-8-yl]-ethanone | GPR30 (GPER1) agonist | |
| B-911 | 4-(6-Bromo-benzo[1,3]dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta[c]quinoline | GPR30 (GPER1) antagonist | |
| B-802 | N-Bromoacetyl-beta-phenethylamine | Cysteine-reactive ligand, alkylating reagent | |
| B-801 | N-Bromoacetylnaphthalene-2-ethylamine | Cysteine-reactive ligand, alkylating reagent | |
| B-803 | N-Bromoacetyltryptamine | Cysteine-reactive ligand, alkylating reagent; reversible inhibitor of melatonin secretion in the pineal gland. | |
| Q-707 | N-(tert-Butyloxycarbonyl)-6-nitro-5-(trimethylstannyl)quipazine | Radioiodinated 5-HT uptake inhibitor precursor | |
| A-513 | N-(tert-Butyloxycarbonyl)alanylalanyl-6-hydroxydopamine | Analog of 6-Hydroxydopamine, a neurotoxin used to induce Parkinson's disease | |
| C-501 | 10-Carboethoxy-2-chlorophenothiazine | Cholinesterase Inhibitor | |
| C-148 | (-)-2-beta-Carbomethoxy-3-beta-(4-iodophenyl)tropane D-tartrate | Dopamine reuptake inhibitor | |
| C-801 | (2S,1'S,2'S)-2-(Carboxycyclopropyl)glycine | Metabotropic glutamate mGluR2 receptor agonist | |
| C-105 | CGS 19755 | Competitive NMDA receptor antagonist; anticonvulsant and anti-ischemic | |
| C-901 | CGS 21680 hydrochloride | Adenosine A2 receptor agonist | |
| P-503 | 2-Chloro-10-(2-dimethylaminoethyl)phenothiazine hydrochloride | Chlorpromazine analog | |
| P-504 | 2-Chloro-10-(3-dimethylamino-2-hydroxypropyl)phenothiazine hydrogen maleate | Chlorpromazine analog | |
| C-536 | 6-Chloro-2-methylmelatonin | Melatonin receptor antagonist | |
| D-524 | DL-2-Chloro-3,4-dihydroxyphenylalanine Hydrobromide | L-DOPA analog | |
| D-525 | DL-6-Chloro-3,4-dihydroxyphenylalanine hydrobromide | L-DOPA analog | |
| D-518 | DL-3-Chloro-4,5-dihydroxyphenylalanine hydrobromide | beta-Phenylalanine derivative | |
| C-802 | (RS)-2-Chloro-5 hydroxyphenylglycine | Metabotropic glutamate mGlu5 receptor agonist | |
| P-505 | 2-Chloro-6,9-dioxophenothiazine | Possible chlorpromazine metabolite | |
| P-506 | (±)-2-Chloro-7,8-dioxo-10-(3-dimethylamino-2-hydroxypropyl)phenothiazine hydrochloride | Possible chlorpromazine metabolite | |
| C-708 | Chloro-IB-MECA | Adenosine A3 agonist with potential antineoplastic activity | |
| I-501 | 3-Chloro-N-desmethylimipramine hydrochloride | Antidepressant | |
| A-509 | N-(3-Chlorophenyl)-N-[gamma-N',N'-dimethylaminopropyl]aniline hydrochloride | Inhibitor of dopamine activated adenylase cyclase cAMP phosphodiesterase | |
| C-538 | 4-Chloro-DL-phenylalanine | Selective and irreversible inhibitor of tryptophan hydroxylase | |
| C-537 | 2-Chloropropadrine hydrochloride | Vasoconstrictor | |
| C-806 | Chlorphentermine hydrochloride | Serotonergic appetite suppressant of the amphetamine family | |
| C-503 | Chlorpromazine hydrochloride | Dopamine, 5-HT, histamine, adrenaline, & muscarinic receptor antagonist, antipsychotic, antiemetic | |
| C-529 | nor1-Chlorpromazine hydrochloride | Chlorpromazine metabolite | |
| C-530 | nor2-Chlorpromazine hydrochloride | Active metabolite of chlorpromazine | |
| C-526 | Chlorpromazine sulfone hydrochloride | Chlorpromazine metabolite | |
| C-524 | Chlorpromazine sulfoxide hydrochloride | Antiemetic; antipsychotic agent; dopamine antagonist | |
| C-532 | nor1-Chlorpromazine sulfoxide hydrochloride | Chlorpromazine metabolite | |
| C-531 | nor2-Chlorpromazine sulfoxide hydrochloride | Chlorpromazine metabolite | |
| C-701 | Chlorpromazine-10-spermidine Dihydrochloride | Potential prodrug for polyamines | |
| C-525 | Chlorpromazine-N-oxide | Antiemetic; antipsychotic agent; dopamine antagonist | |
| C-707 | Chrysamine G | beta-Amyloid ligand | |
| C-908 | Ciproxifan | Histamine H3 receptor antagonist | |
| C-904 | Clopidogrel hydrogen sulfate | Irreversible purinergic P2Y12 receptor inhibitor with antiplatelet activity | |
| C-905 | Clorgyline hydrochloride | Antidepressant; monoamine oxidase inhibitor | |
| C-807 | Clozapine | Selective dopamine D4 receptor antagonist, atypical antipsychotic used to treat schizophrenia | |
| C-910 | Coenzyme A-S-acetyl-2-naphthylen-1-ylethylamine | Ligand for melatonin rhythm enzyme arylalkylamine-N-acetyltransferase (AANAT) | |
| C-902 | Coenzyme A-S-acetyl-L-DOPA | DOPA conjugate | |
| C-920 | 6-Cyano-7-nitroquinoxaline-2,3-dione Disodium Salt | AMPA/kainate receptor antagonist | |
| C-706 | Cyanopindolol fumarate | beta1-Adrenergic and 5-HT1A receptor antagonist | |
| C-919 | Cyclohexylcarbamic Acid 3’-Carbamoylphenyl-3-yl Ester | Fatty-acid amide hydrolase (FAAH) inhibitor | |
| C-804 | (RS)-alpha-Cyclopropyl-4-phosphonophenylglycine | Metabotropic glutamate mGluR3 receptor antagonist | |
| C-702 | 5-(S)-Cysteinyl-L-DOPA | melanoma biomarker | |
| C-903 | 5-(S)-Cysteinyl-DOPAC hydrochloride | Dopamine metabolite | |
| C-805 | 5-(S)-Cysteinyldopamine | May be involved in neural degeneration characteristic of Parkinson's disease; dopamine metabolite | |
| D-803 | DASB hydrochloride | Serotonin transporter ligand, PET ligand precursor | |
| Y-705 | (±)-5-Deschloro-4-desmethyl-YM-09151-2 | Precursor to radiolabeled 4-azido-5-iodo-YM-09151-2 | |
| T-902 | (+)-(2R,3R,11bR)-9-O-Desmethyl-alpha-dihydrotetrabenazine | Starting material for synthesis of carbon-11 labeled (+)-alpha-dihydrotetrabenazine ([11C]DTBZ) | |
| D-804 | Desmethyl-DASB | DASB PET ligand precursor (cf. D-803) | |
| N-704 | (+)-N-Desmethyl-NNC 01-0112 hydrochloride | NNC-01-0112 PET ligand precursor | |
| T-511 | N-Desmethyltriflupromazine hydrochloride | Chlorpromazine analog | |
| P-520 | 3,4-Di(beta-dimethylaminoethoxy)-beta-phenethylamine trihydrochloride | ||
| D-521 | 3,4-Di(beta-trimethylammoniumethoxy)-beta-phenethylamine Dichloride Hydrochloride | Dopamine derivative | |
| C-506 | 7,8-Diacetoxychlorpromazine hydrogen maleate | Chlorpromazine analog | |
| P-519 | 1,4-Diacryloylpiperazine | Cross-linking monomer for development of polyacrylamide gels | |
| Q-901 | 2-[2-(4-Dibenzo[b,f][1,4]thiazepine-11-yl-1-piperazinyl)ethoxy]ethanol fumarate | Dopamine, serotonin, & adrenergic antagonist; antihistaminic, an atypical antipsychotic medication used for the treatment of schizophrenia, bipolar disorder, and major depressive disorder. | |
| D-514 | L-3,4-Dibenzoyloxyphenylalanine | Inhibitor of monoamine oxidase and the synaptosomal uptake of dopamine | |
| P-514 | 2,4-Dibenzyloxy-5-methoxyphenylacetic acid | ||
| P-521 | 3,4-Dibenzyloxy-beta-phenethylamine hydrochloride | Dopamine derivative | |
| C-508 | 7,8-Dibenzyloxychlorpromazine | Chlorpromazine analog | |
| D-702 | 3-(4',4''-Dibromobenzhydryloxy)tropane hydrochloride | Dopamine uptake inhibitor | |
| D-802 | (2S,1'R,2'R,3'R)-2-(2',3'-Dicarboxylcyclopropyl)glycine | Anticonvulsant; selective group II mGluR agonist | |
| B-711 | 2',4'-Dichlorobenzamil hydrochloride | Sodium/calcium exchanger inhibitor | |
| B-710 | 3',4'-Dichlorobenzamil hydrochloride | Sodium/calcium exchanger inhibitor | |
| D-529 | 2,4-Dichloropromazine hydrochloride | Chlorpromazine analog | |
| I-502 | N,N-Didesmethylimipramine hydrochloride | Imipramine metabolite | |
| R-501 | 1-(beta-Diethylamino)ethylreserpine dipicrate | Anticancer and hypotensive agent | |
| D-522 | 3,4-Diethylcarbonato-beta-phenethylamine carbamate | Dopamine derivative | |
| D-904 | d2-Dihydroouabain | Stable isotope labeled dihydroouabain | |
| D-905 | (-)-alpha-Dihydrotetrabenazine | Optical isomer of putative tetrabenazine metabolite alpha-dihydrotetrabenazine | |
| T-802 | (+)-alpha-Dihydrotetrabenazine | Active metabolite of tetrabenazine with high affinity for the vesicular monamine transporter (VMAT2) | |
| D-701 | (±)-5,6-Dihydroxy-2-(N,N-dimethyl)aminotetralin hydrobromide | Dopamine analog | |
| D-519 | 2,3-Dihydroxy-beta-phenethylamine hydrobromide | Positional isomer of dopamine | |
| D-520 | 2,4-Dihydroxy-beta-phenethylamine hydrochloride | Positional isomer of dopamine | |
| C-512 | 7,8-Dihydroxy-N,N-didesmethylchlorpromazine hydrochloride | Chlorpromazine analog | |
| H-512 | DL-2-(3,4-Dihydroxybenzyl)-2-hydrazinopropionic Acid | Aromatic-l-amino-acid decarboxylase inhibitor, used in Parkinson's Disease to reduce peripheral adverse effects of Levodopa | |
| C-511 | 7,8-Dihydroxychlorpromazine hydrochloride | Chlorpromazine analog | |
| D-509 | 5,6-Dihydroxyindole | Catechol O-methyltransferase (COMT) inhibitor, dopamine metabolite | |
| P-501 | 7,8-Dihydroxyperphenazine dihydrochloride | Chlorpromazine metabolite | |
| S-501 | D-(+)-threo-3-(3,4-Dihydroxyphenyl)serine | Monoamine oxidase inhibitor | |
| S-502 | L-(-)-threo-3-(3,4-Dihydroxyphenyl)serine | ||
| D-515 | (+)-2,4-Dihydroxyphenylalanine | Enantiomer of L-DOPA | |
| D-517 | (-)-2,4-Dihydroxyphenylalanine | Tyrosinase inhibitor | |
| D-512 | (±)-2,4-Dihydroxyphenylalanine | Racemic mixture of L-DOPA, the precursor to the neurotransmitters dopaminem, norepinephrine, and epinephrine | |
| D-516 | DL-3,4-Dihydroxyphenylalanyl-GABA | GABA adduct | |
| D-505 | 3,4-Dihydroxyphenylethanol,1,4-Diazabicyclo[2.2.2]octane salt | Naturally occurring phenolic phytochemical with potential antioxidant, anti-inflammatory and cancer preventive activities | |
| D-506 | 3,4-Dimethoxy-5-hydroxybenzoic acid | Thiopurine methyltransferase inhibitor | |
| P-522 | 2,5-Dimethoxy-beta-phenethylamine hydrochloride | Phenethylamine derivative | |
| C-513 | 7,8-Dimethoxychlorpromazine hydrochloride | Chlorpromazine analog | |
| D-916 | 3-(2,5-Dimethoxyphenyl)-6-(3,4-dimethoxy¬phenyl)-7H-[1,2,4]triazolo[3,4-b][1,3,4]thiadiazine | Phosphodiesterase type 4 (PDE4) inhibitor | |
| P-515 | 2,4-Dimethoxyphenylacetic acid | Dopamine analog | |
| D-528 | DL-(N,N-Dimethyl)ephedrine iodide | Choline acetyltransferase inhibitor | |
| F-902 | N,N-Dimethyl-2-(2-amino-4-fluorophenylthio)benzylamine | Serotonin transporter PET ligand reference standard | |
| D-507 | alpha-Dimethylamino-3,4-dihydroxyacetophenone methachloride | Quarternary trimethylammonium salt related to dopamine and noradrenaline | |
| I-902 | 2-(4’-N,N-Dimethylaminophenyl)-6-(tributylstannyl)imidazo[1,2-a]pyridine | Radio-iodinated IMPY precursor | |
| I-901 | 2-(4’-N,N-Dimethylaminophenyl)-6-iodoimidazo[1,2-a]pyridine | Beta-amyloid aggregate-specific ligand, PET tracer precursor | |
| D-915 | 2-(3-Dimethylaminophenyl)-7,8-dihydroxy-4H-chromen-4-one | Tropomyosin-related kinase (TrkB) agonist | |
| D-513 | 4-(gamma-N,N-Dimethylaminopropylamino)phenol Dimaleate | Antiozonant | |
| H-518 | N,N-Dimethylhistamine methiodide | Histamine derivative | |
| I-705 | 1,2-Dimethylisoquinolinium iodide | ||
| C-514 | 7,8-(Dimethylmethylenedioxy)chlorpromazine | Chlorpromazine analog | |
| C-907 | N,N-Dinorcitalopram oxalate | Citalopram metabolite | |
| C-516 | 7,8-Dioxo(N,N-didesmethyl)chlorpromazine hydrochloride | Chlorpromazine analog | |
| C-515 | 7,8-Dioxochlorpromazine hydrochloride | Chlorpromazine analog | |
| D-805 | 1,2-Dithiole-3-thione | Antineoplastic agent | |
| B-705 | (R)-(+)-5-(1,3-Dimethylbutyl)-5-ethylbarbituric Acid | Sedative, hypnotic | |
| B-704 | (S)-(-)-5-(1,3-Dimethylbutyl)-5-ethylbarbituric Acid | Sedative, hypnotic | |
| D-901 | L-DOPA-ring-d3 | Stable isotope labeled l-DOPA. | |
| G-502 | Dopamine-4-O-beta-D-glucuronide | ||
| D-504 | Dopamine-4-O-sulfate | Dopamine metabolite | |
| E-704 | EHPG piperazine salt | Catecholamine turnover biomarker | |
| E-709 | (E)-2-Enevalproate, sodium salt | Valproic acid metabolite | |
| E-708 | (E)-2-Enevalproic Acid | Anticonvulsant; valproic acid metabolite | |
| E-703 | Epidepride | Dopamine D2 receptor antagonist, precursor of PET tracer | |
| C-502 | N-Ethyl-2-chlorophenothiazine | Cholinesterase inhibitor | |
| T-506 | 5-Ethyl-5-(1'-methyl-3'-hydroxybutyl)-2-thiobarbituric Acid | Thiopental metabolite | |
| B-501 | 5-Ethyl-5-(3’-hydroxy-1’-methylbutyl)barbituric Acid | Pentobarbitol metabolite | |
| E-706 | DL-alpha-Ethylmethionine-(S,R)-sulfoximine | Glutamate synthetase inhibitor | |
| E-701 | N-Ethylnornicotine | Nicotine analog, internal standard for mass spectrometry | |
| F-901 | FK866 | Nicotinamide phosphoribosyltransferase inhibitor | |
| N-502 | 6-Fluoronorepinephrine oxalate | alpha-and beta-Adrenergic receptor agonist | |
| F-908 | 1-(2-(4-(1-(4-Fluorophenyl)-5-(1-methyl-1H-1,2,4-triazol-5-yl)-1H-indol-3-yl)-1-piperidinyl)ethyl)imidazolidin-2-one | alpha1-Adrenoceptor antagonist; a1-adrenoceptor PET ligand reference standard | |
| F-909 | 1-(2-(4-(1-(4-Fluorophenyl)-5-(1H-1,2,4-triazol-5-yl)-1H-indol-5-yl)-1-piperidinyl)ethyl)imidazolidin-2-one | alpha1-Adrenoceptor PET ligand labeling precursor | |
| F-132 | (±)-Fluoxetine Hydrochloride | Serotonin uptake inhibitor; second-generation antidepressant | |
| G-801 | GBR 12909 dihydrochloride | Dopamine reuptake inhibitor with behavioral effects similar to cocaine | |
| G-501 | gamma-Glutamyldopamine | Kidney-specific prodrug of L-DOPA and dopamine | |
| G-802 | gamma-L-Glutamylserotonin | Serotonin derivative | |
| M-903 | [(-)-(R)-Methyl 4-[(3,4-dichlorophenyl)acetyl]-3-[(1-pyrrolidinyl)methyl]-1-piperazinecarboxylate fumarate | Kappa-opioid receptor agonist | |
| H-520 | 2-Hydrazino-3-(4-hydroxyphenyl)propionic acid | Potential antipsychotic; competitive inhibitor of fungal tyrosinase | |
| B-804 | N-[2-(7-Hydroxy-1-naphthyl)ethyl]-2-bromoacetamide | Cysteine-reactive ligand, alkylating reagent, N-acetyltransferase (AANAT) inhibitor | |
| H-903 | N-[2-(7-hydroxy-1-naphthyl)ethyl]amine hydrochloride | Serotonin N-acetyltransferase inhibitor | |
| H-902 | 2-(5-Hydroxy-1H-indol-3-ylmethyl)thiazolidine-4-carboxylic Acid potassium salt | Serotonin metabolite | |
| H-904 | 6-Hydroxy-2-(4-hydroxyphenyl)-3-[(2E,6E)-3,7,11-trimethyl-dodeca-2,6,10-trienyl]-[1,4]-naphthoquinone | Estrogen receptor modulator | |
| R-701 | 17alpha-Hydroxy-20alpha-yohimban-16beta-(N-4-aminophenethyl)carboxamide dihydrochloride | Adrenergic ?2 ligand radioiodination precursor | |
| H-523 | 4(3)-Hydroxy-3(4)-(beta-dimethylaminoethoxy)-beta-phenethylamine Dihydrochloride | beta-phenethylamine derivative | |
| H-527 | 4(3)-Hydroxy-3(4)-(beta-trimethylammoniumethoxy)-beta-phenethylamine chloride hydrochloride | beta-Phenethylamine derivative | |
| H-515 | beta-(5-Hydroxy-3-benzo[b]thienyl)-alpha-aminopropionic acid | Inhibitor of DOPA decarboxylase | |
| H-908 | {4-[4-hydroxy-3-isopropyl-5-(4-nitrophenylethynyl)benzyl]-3,5-dimethylphenoxy}acetic acid | beta-subtype selective thyroid hormone receptor antagonist | |
| H-513 | 3-(4-Hydroxy-3-methoxyphenyl)-1-propanol | Phenolic plant metabolite | |
| P-528 | (±)-4-Hydroxy-3-methoxyphenylpropyleneglycol 1,4-Diazabicyclo[2.2.2]octane | lignin model compound | |
| P-526 | 3-Hydroxy-4-methoxy-DL-phenylalanine | Phenethylamine derivative | |
| H-502 | 5-Hydroxy-6-methoxytryptamine creatinine sulfate | 5-Hydroxytryptamine derivative | |
| H-503 | 5-Hydroxy-7-methoxytryptamine creatinine sulfate | 5-Hydroxytryptamine derivative | |
| H-522 | 2-Hydroxy-beta-phenethylamine hydrochloride | beta-phenethylamine derivative, Trace amine receptor 1 (TAAR1) ligand | |
| H-701 | (±)-7-Hydroxy-DPAT hydrobromide | Selective D3 dopamine agonist | |
| H-704 | (R)-(+)-7-Hydroxy-2-(N,N-dipropylamino)tetralin hydrobromide | Dopamine receptor antagonist | |
| C-520 | 7-Hydroxy-N-desmethylchlorpromazine hydrochloride | Chlorpromazine metabolite | |
| I-504 | 2-Hydroxy-N-desmethylimipramine | Tricyclic antidepressant; imipramine metabolite | |
| H-705 | (±)-trans-7-Hydroxy-PIPAT hydrochloride | Dopamine D3 receptor agonist | |
| H-521 | 3-Hydroxybenzylamine | GABA receptor antagonist | |
| C-518 | 7-Hydroxychlorpromazine hydrochloride | Antiemetic; antipsychotic agent; dopamine antagonist | |
| C-521 | 7-Hydroxychlorpromazine methiodide | antiemetic; antipsychotic agent; dopamine antagonist | |
| C-528 | 7-Hydroxychlorpromazine sulfoxide | Chlorpromazine metabolite | |
| C-519 | 7-Hydroxychlorpromazine-O-beta-D-glucuronide | 7-hydroxychlorpromazine metabolite | |
| D-501 | 6-Hydroxydopamine hydrobromide | Catecholaminergic neurotoxin | |
| D-502 | 6-Hydroxydopamine hydrochloride | Catecholaminergic neurotoxin | |
| C-803 | 7-(Hydroxyimino)cyclopropa[b]chromen-1a-carboxylate Ethyl Ester | Metabotropic glutamate mGluR1 receptor antagonist | |
| I-503 | 2-Hydroxyimipramine | Imipramine metabolite | |
| H-501 | 5-Hydroxyindole-3-beta-propionic acid | GC/MS internal standard for catecholamine assay | |
| H-516 | 3-(3-Hydroxyphenyl)-N-(n-propyl)piperidine hydrobromide | Dopamine autoreceptor agonist, antiparkinson agent; dopaminergic agent | |
| H-526 | threo-beta-(4-Hydroxyphenyl)serine | Phenylethanolamine derivative, potential quorum sensing inhibitor | |
| H-901 | 4-Hydroxyphenylacetaldehyde | Tyrosine metabolite | |
| H-528 | 4-Hydroxyphenylglycol | Octopamine metabolite | |
| H-113 | 2-Hydroxysaclofen | gamma-Aminobutyric acid GABAB antagonist | |
| H-907 | (Z)-4-Hydroxytamoxifen | Estrogen receptor antagonist | |
| H-504 | 4-Hydroxytryptamine creatinine sulfate | 5-Hydroxytryptamine derivative | |
| H-505 | 6-Hydroxytryptamine creatinine sulfate | 5-Hydroxytryptamine derivative | |
| H-510 | 4-Hydroxytryptophan hemiacetate | Tryptophan derivative | |
| I-801 | IDAM hydrochloride | Unlabeled analog of a SPECT serotonin transporter imaging agent | |
| I-709 | Inositol Phosphate, Arylbis(phosphonate) analog, dipotassium salt | Non-hydrolysable inhibitor of myo-inositol monophosphatase | |
| Q-708 | 5-Iodo-6-nitroquipazine | Selective 5-HT uptake inhibitor | |
| M-144 | (+)-3-Iodo-MK-801 hydrochloride | NMDA antagonist MK-801 analog | |
| M-141 | (-)-3-Iodo-MK-801 hydrochloride | NMDA antagonist MK-801 analog | |
| Y-706 | (±)-4'-Iodo-YM-09151-02 | Potential high affinity probe for dopamine D2 receptors | |
| I-701 | IsoMHPG | Noradrenaline metabolite | |
| I-906 | (R)-2-Isopropylpentanoic acid | (R)-enantiomer of non-teratogenic constitutional isomer of the anticonvulsant drug valproic acid. | |
| I-907 | (S)-2-Isopropylpentanoic Acid | (S)-enantiomer of a non-teratogenic constitutional isomer of the anticonvulsant drug valproic acid | |
| I-505 | (±)-Isosalsoline hydrochloride | Tetrahydroisoquinoline derivative active at TRPV receptors, monoamine oxidases A and B, and inhibits NO production | |
| I-124 | Isradipine | Antihypertensive agent; calcium channel blocker; vasodilator | |
| J-901 | JMV-431 | Neurotensin receptor subtype 2 agonist | |
| K-501 | Kawain | Anticonvulsant; anxiolytic | |
| K-701 | Kemptide Fluorescein | Fluorescently-labeled marker for protein kinase A (PKA) | |
| L-901 | beta-Lactotensin | Neurotensin receptor subtype 2 agonist. | |
| M-901 | (+)-McN-5652 S-Desmethyl-S-butyryl ester D-tartrate | (+)-McN-5652 PET ligand precursor | |
| M-706 | (+)-McN-5652 S-Desmethyl-S-butyryl ester | (+)-McN-5652 PET ligand precursor | |
| M-707 | (+)-McN-5652 | Serotonin transporter inhibitor (active enantiomer) | |
| M-708 | (-)-McN-5652 | Serotonin transporter inhibitor (inactive enantiomer) | |
| M-704 | (±)-McN-5652 | Serotonin transporter inhibitor | |
| M-802 | L-anti-endo-3,4-Methaneopyrrolidinedicarboxylic Acid | Inhibitor of the Na-dependen, high-affinity synaptosomal Glu transporter | |
| M-902 | 5-Methoxy-1-isopropyltryptamine oxalate | Serotonin analog | |
| M-501 | 1-(3-Methoxy-4-hydroxyphenyl)-1-hydroxy-2-aminopropane hydrogen oxalate | Norepinephrine derivative | |
| M-508 | DL-3-Methoxy-alpha-methyl-DOPA-4-O-sulfate, potassium salt | L-alpha-methyldopa derivative | |
| C-523 | 7-Methoxychlorpromazine hydrochloride | Chlorpromazine metabolite | |
| M-506 | 6-Methoxymelatonin | 6-hydroxymelatonin metabolite | |
| P-509 | 2-Methoxyphenothiazine | Phenothiazine derivative | |
| M-503 | 6-Methoxytryptamine creatinine sulfate | Serotonin derivative | |
| I-703 | (±)-1-Methyl-1,2,3,4-tetrahydroisoquinoline hydrochloride | Potential dopaminergic neurotoxin | |
| M-804 | (2S,3S,4S)-2-Methyl-2-(carboxycyclopropyl)glycine | Metabotropic glutamate mGluR2 antagonist | |
| P-511 | N-Methyl-2-(trifluoromethyl)phenothiazine | Phenothiazine derivative | |
| M-701 | 1-Methyl-4-(2’-methylphenyl)pyridinium iodide | 2'-methyl-MPTP metabolite, neurotoxin, vesicular monoamine transporter ligand | |
| D-503 | 2-Methyl-6-hydroxydopamine hydrobromide | Catecholaminergic neurotoxin | |
| B-504 | N-Methyl-N-(1-methyl-4-pyrrolidino-2-butynyl)acetamide oxalate | Muscarinic partial agonist (oxotremorine analog) | |
| M-509 | (±)-2-Methylamino-1-phenylethanol | Monoamine oxidase A &B substrate | |
| E-707 | L-N-Methylepinephrine L-tartrate | Epinephrine derivative | |
| M-507 | (R)-(-)-alpha-Methylhistamine 1.5 Oxalate | Histamine H3 agonist | |
| H-517 | 2-Methylhistamine dipicrate | Histamine agonist | |
| H-509 | 4-Methylhistidine hydrochloride | Histidine analog | |
| H-507 | alpha-Methylhistidine hydrochloride | Histidine decarboxylase inhibitor | |
| I-704 | 1-Methylisoquinoline hydrochloride | Potential dopaminergic neurotoxin | |
| P-510 | N-Methylphenothiazine | Phenothiazine derivative | |
| M-803 | (RS)-alpha-Methylserine-O-phosphate | Metabotropic glutamate mGluR antagonist | |
| M-710 | 1-Methylserotonin hydrogen maleate | Serotonin analog | |
| M-504 | alpha-Methylserotonin hydrogen oxalate | Serotonin 5-HT2B agonist | |
| M-709 | 1-Methyltryptamine hydrochloride | Methylated tryptamine | |
| M-711 | 5-Methyltryptamine hydrogen maleate | Serotonin analog | |
| M-712 | 6-Methyltryptamine hydrogen maleate | Serotonin analog | |
| M-510 | N-Methyltyramine hydrobromide | Human biogenic trace amine | |
| M-703 | Mifepristone | Progesterone receptor antagonist; stimulates prolactin secretion | |
| M-107 | (+)-MK-801 hydrogen maleate | Selective, non-competitive NMDA glutamate receptor antagonist | |
| M-916 | 2-(4-Morphin-4-ylphenyl)-7,8-dihydroxy-4H-chromen-4-one | 7,8-Dihydroxyflavone analog. | |
| C-912 | N-Caffeoylnorepinephrine | Norepinephrine adduct | |
| C-911 | N-Cinnamoylnorepinephrine | Norepinephrine adduct | |
| C-913 | N-Coumaroyldopamine | Free radical scavenger, monoamine oxidase inhibitor, cholinesterase inhibitor | |
| C-914 | N-Coumaroyloctopamine | Free radical scavenger, antioxidant, anti-inflammatory | |
| F-903 | N-feruloylnorepinephrine | Norepinephrine derivative | |
| F-904 | N-Feruloyltyramine | Alkaloid derivative in many natural products | |
| T-702 | (R)-(-)-N-Methyl-3-(2-iodophenoxy)-3-phenylpropanamine hydrochloride | Norepinephrine transport inhibitor | |
| N-801 | (±)-N-Norfenfluramine hydrochloride | Serotonin releaser, 5-HT2B agonist | |
| N-802 | (R)-(-)-N-Norfenfluramine hydrochloride | Serotonin reuptake inhibitor | |
| N-803 | (S)-(+)-N-Norfenfluramine hydrochloride | Serotonin uptake inhibitor | |
| C-909 | (R)-(+)-N-trans-p-Coumaroylnoradrenaline | Plant metabolite implicated in tomato defense against pathogens | |
| N-901 | (±)-Nisoxetine hydrochloride | Norepinephrine uptake inhibitor | |
| N-705 | 6-Nitrodopamine | Nitrated catecholamine | |
| N-706 | 6-Nitronorepinephrine | Nitrated catecholamine | |
| N-703 | (+)-NNC 01-0112 | Dopamine D1 receptor ligand | |
| N-904 | R-(-)-Norapomorphine hydrobromide | Dopamine receptor agonist and PET ligand labeling precursor | |
| C-906 | N-Norcitalopram oxalate | Citalopram metabolite | |
| N-702 | (+)-Norepinephrine (+)-tartrate | Unnatural enantiomer of norepinephrine | |
| N-707 | Norepinephrine-3-O-sulfate | Catechol O-methyltransferase inhibitor | |
| D-902 | (±)-O-Desethylreboxetine | Reboxetine PET ligand precursor | |
| O-501 | D-(-)-Octopamine | Norepinephrine derivative, a biogenic amine formed by ?-hydroxylation of tyramine, found naturally in many plants, used as sympathomimetic drug | |
| O-901 | Olanzapine | Dopamine and serotonin receptor inhibitor, an atypical antipsychotic used to treat schizophrenia and bipolar disorder | |
| P-710 | PD149163 | Selective, brain penetrating neurotensin NTR1 receptor agonist with pro-cognitive, antipsychotic and anxiolytic effects. Neurotensin (8-13) analog. | |
| P-512 | Phenothiazine-5-oxide | Phenothiazine matebolite | |
| P-801 | (±)-4-Phenyl-2-(propioamido)tetralin | Melatonin receptor antagonist | |
| P-804 | (±)-4-Phenyl-2-[2',2',3'-2H]-(propioamido)tetralin | Deuterated melatonin receptor antagonist | |
| P-805 | N-(1-benzylpiperidin-4-yl)-N-methyl-3-propan-2-yloxypyridin-2-amine dihydrochloride | Dopamine D4 antagonist | |
| P-513 | nor1-Promazine sulfoxide hydrochloride | Chlorpromazine metabolite | |
| P-707 | (R)-(+)-2-(N-Propargyl-N-propyl)amino-7-hydroxytetralin hydrochloride | Radiolabeling (R)-(+)-7-hydroxy-DPAT precursor | |
| P-708 | (R)-(-)-2-(N-Propargyl-N-propyl)amino-8-hydroxytetralin Hydrochloride | precursor to radiolabeled (R)-(Ð)-8-hydroxy-DPAT | |
| D-041 | (S)-(+)-N-Propylnorapomorphine hydrochloride | Limbic-selective dopamine receptor antagonist | |
| P-803 | 3-(R)-[2-(S)-(Pyrrolidinylcarbonyl)amino]-2-oxo-1-pyrrolidineacetamide | D2 allosteric modulator | |
| R-902 | (±)-Reboxetine mesylate | Noradrenaline reuptake inhibitor used as an antidepressant | |
| R-901 | Risperidone | Serotonin 5HT2 and dopamine D2 antagonist, an atypical antipscyhotic used to treat schizophrenia, bipolar disorder, and irritability associated with autism | |
| R-702 | 5-Methoxy-3-(1,2,3,6-tetrahydro-4-pyridinyl)-1H-indole hemisuccinate | Serotonin 5-HT1A/1B agonist. | |
| S-504 | (±)-Salsoline hydrochloride | Salsolinol metabolite; endogenous neurotoxin | |
| S-505 | (±)-Salsolinol hydrochloride | Neurotoxic derivative of dopamine | |
| S-803 | Serotonin-O-beta-D-glucuronide | Serotonin metabolite | |
| S-503 | Serotonin-O-sulfate | Serotonin metabolite | |
| S-905 | SIB-1508Y | alpha-4-beta-2 subtype selective neural nicotinic acetylcholine receptor agonist | |
| S-903 | SIB-1553A | Nicotinic acetylcholine receptor agonist with selectivity for beta-4 subunit-containing receptors; possible cognitive enhancer | |
| S-701 | SKF-104078 | Adrenergic alpha-2 antagonist | |
| S-101 | (R)-(+)-SKF-38393 hydrochloride | D1 dopamine receptor agonist; active enantiomer of (±)-SKF-38393 | |
| S-906 | SKF-81297 hydrobromide | Dopamine D1 receptor agonist | |
| S-907 | SKF-82958 hydrobromide | Dopamine D1 receptor agonist | |
| S-904 | SKF-83822 hydrobromide | Dopamine D1 receptor agonist | |
| S-706 | SKF-83959 hydrobromide | Dopamine D1 receptor agonist | |
| S-901 | Spiperone | Serotonin 5-HT1A, 5-HT2A, 5-HT7, and dopamine D2 antagonist, a typical antipsychotic used to treat schizophrenia | |
| S-705 | SR 141716 | Cannabinoid CB1 receptor inverse agonist used an anorectic anti-obesity drug | |
| S-902 | SR 142948 | Neurotensin receptor antagonist | |
| S-801 | SR 144528 | CB2 cannabinoid receptor inverse agonist | |
| S-802 | SR 48692 | Neurotensin NT1 antagonist | |
| S-908 | SR147778 | Cannabinoid CB1 receptor antagonist | |
| A-702 | N6-p-Sulfophenyladenosine triethylamine salt | Water-soluble adenosine A1 agonist | |
| T-905 | (+)-Tetrabenazine | Dopamine depleting agent; optical isomer of tetrabenazine | |
| T-904 | (-)-Tetrabenazine | Dopamine depleting agent; optical isomer of tetrabenazine | |
| T-901 | (±)-Tetrabenazine | Reversible monoamine depleting agent, used to treat chorea associated with Huntington's disease and hyperkinetic movement disorders. | |
| I-702 | 1,2,3,4-Tetrahydroisoquinoline hydrochloride | Potential dopaminergic neurotoxin | |
| T-703 | 1-[1-(2-Thienyl)cyclohexyl]morpholine | PCP analog | |
| T-906 | Thioperamide maleate | CNS penetrant inhibitor of histamine H3 and H4 receptors | |
| T-907 | Tolcapone | Nitrocatechol-type inhibitor of the enzyme catechol-O-methyltransferase (COMT) used to treat Parkinson's disease | |
| B-901 | trans-Bis-Q [trans-3,3'-bis[alpha-trimethylammonum)methyl]azobenzene dibromide] | Photochromic acetylcholine receptor activator | |
| A-808 | Tributylstannyl-ADAM | Radioiodinated ADAM precusor | |
| T-501 | Trifluoperazine-5-oxide | Trifluoperazine metabolite | |
| T-507 | 2,3,4-Trihydroxy-beta-phenylethylamine hydrochloride | potential neurotoxin; arylsulfatase inhibitor | |
| T-508 | 2,3,4-Trihydroxy-DL-phenylalanine | Neurotoxic DOPA metabolite | |
| H-511 | 5-(2,4,5-Trihydroxybenzyl)hydantoin | ||
| T-503 | 5,6,7-Trihydroxytryptamine creatinine sulfate | Tryptamine derivative | |
| D-510 | 5,6,7-Trimethoxy-N,N-dimethyltryptamine | ||
| P-516 | 3,4,5-Trimethoxyphenylacetic Acid | Mescaline metabolite | |
| M-145 | (+)-3-Trimethylsilyl-MK-801 hydrochloride | Radioiodinated (+)-3-iodo-MK-801 precursor | |
| M-143 | (-)-3-Trimethylsilyl-MK-801 hydrochloride | Radioiodinated (-)-3-iodo-MK-801 precursor | |
| Y-707 | (±)-4'-Trimethylstannyl-YM-09151-02 | Radioiodinated 4'-iodo-YM-09151-02 precursor | |
| E-705 | 5-Trimethylstannylepidepride | Precursor for radioiodinated epidepride (D2 antagonist) | |
| T-908 | 7alpha-[(4R,8R)-4,8,12-Trimethyltridecyl]estra-1,3,5(10)-trien-3,17beta-diol | A hybrid ligand of 17?-Estradiol and Vitamin E acting on estrogen receptor | |
| U-802 | Tritiated U-101,958 (N-methyl-3H) | ||
| T-704 | Tropapride hydrochloride | Dopamine D2 receptor antagonist | |
| T-502 | L-(-)-Tyrosine-O-sulfate potassium salt | Tyrosine metabolite | |
| U-703 | (S)-(-)-N-Propargyl-UH-301 Hydrochloride | Serotonin receptor antagonist radiolabel precursor | |
| H-703 | Velnacrine maleate | Cholinesterase inhibitor | |
| V-902 | Ethyl 4-{2-[(2-methylbenzoyl)amino]ethylamino}piperidine-1-carboxylate hydrochloride | Muscarinic M1 receptor allosteric modulator | |
| W-501 | N-(6-Aminocyclohexyl)-1-naphthalenesulfonamide hydrochloride | Calmodulin antagonist | |
| W-502 | N-(6-Aminocyclohexyl)-5-chloro-1-naphthalenesulfonamide hydrochloride | calmodulin antagonist | |
| W-901 | WAY 405 | Serotonin 5-HT1A receptor antagonist | |
| W-108 | WAY-100635 maleate | Serotonin 5-HT1A receptor antagonist | |
| W-801 | WRC-0571 | Adenosine A1 receptor antagonist | |
| Y-701 | (±)-YM-09151-2 | Dopamine D2 and D3 receptor antagonist and 5-HT1A receptor agonist, an atypical antipsychotic used to treat schizophrenia | |
| Y-703 | (+)-YM-09151-2 | Active stereoisomer of YM-09151-2, Dopamine D2 and D3 receptor antagonist; 5-HT1A receptor agonist | |
| Y-702 | (-)-YM-09151-2 | Inactive stereoisomer of YM-09151-2 | |
| Z-901 | (±)-Zacopride hydrochloride | Serotonin 5-HT3 receptor antagonist and 5-HT4 receptor agonist, used as antiemetic | |
| Z-902 | Zonisamide | Anticonvulsant |
Since 1959, the NIMH Chemical Synthesis and Drug Supply Program has synthesized and distributed novel research chemicals, psychoactive drugs, and compounds that are unavailable from commercial sources to the scientific community working on research relevant to mental health.